Dr Jianjun Xu | Hepatobiliary Oncology and Cancer | Best Researcher Award

Posted on by Pencis

Dr Jianjun Xu | Hepatobiliary Oncology and Cancer | Best Researcher Award

Union Hospital, Tongii Medical | China

Author Profile

Scopus

Orcid id

🏥 Dr. Jianjun Xu: Pioneering Hepatobiliary Oncology Specialist

👨‍⚕️ Full Name: Jianjun Xu

🏅 Designation: Attending Doctor

🏨 Department:

  • Department of Hepatobiliary Surgery
  • Center for Liver Transplantation

🎓 Qualification: Doctor

🔬 Area of Specialization: Hepatobiliary Oncology and Cancer

💡 Sub Division: Oncology Therapeutics and Novel Approaches

🕒 Total Experience:

  • Work for 2 years
  • Doctor for 3 years
  • Master for 3 years
  • Bachelor for 5 years

 

🎓 Education

📚 2011-2016: Bachelor of Clinical Medicine, School of Medicine, Nanchang University.

🎓 2016-2019: Master of Surgery, Tongji Medical College, Huazhong University of Science and Technology.

🏫 2019-2022: Doctor of Surgery, Tongji Medical College, Huazhong University of Science and Technology.

🏥 Experience

🩺 July 2022 to Present: Attending Doctor at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Wuhan 430022, China.

🔬 Contributions to Research, Innovations, and Extension Activities On Hepatobiliary Oncology and Cancer

Throughout his tenure, Dr. Jianjun Xu has made significant contributions to Tumor Research & Development, Innovations, and Extension Activities. Actively participating in research projects, he has advanced the understanding of tumor biology, therapeutic interventions, and patient care outcomes. Leveraging his expertise in hepatobiliary malignancies, Dr. Xu collaborates with interdisciplinary teams to identify novel biomarkers, therapeutic targets, and treatment modalities, aiming to improve patient outcomes and quality of life.

Dr. Xu has also been involved in innovative initiatives to translate research findings into clinical practice. By fostering partnerships with industry stakeholders, academic institutions, and healthcare providers, he has facilitated the development and implementation of cutting-edge technologies and treatment approaches in oncology.

In addition to his research endeavors, Dr. Xu actively engages in extension activities to disseminate knowledge and promote awareness of cancer prevention, early detection, and treatment options within the community. Through educational workshops, public seminars, and outreach programs, he empowers patients, caregivers, and healthcare professionals with the necessary information and resources to combat cancer effectively. His dedication to advancing cancer research, innovation, and community outreach underscores his commitment to making a meaningful impact in the fight against cancer.

NOTABLE PUBLICATION:

Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma

Citation: 52        Year: 2021

High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma

Citation: 18        Year: 2022

Systemic immune-inflammation index predicts postoperative acute kidney injury in hepatocellular carcinoma patients after hepatectomy

Citation: 09        Year: 2021

Laparoscopic resection of hepatic epithelioid hemangioendothelioma: report of eleven rare cases and literature review

Citation: 05        Year: 2020

Light-triggered polymeric prodrug and nano-assembly for chemo-photodynamic therapy and potentiate immune checkpoint blockade immunotherapy for hepatocellular carcinoma

Citation: 02        Year: 2023

Prof Dr. ClausGarbe – Oncology Management and Prevention – Lifetime achievement Award

Posted on by Pencis

Prof Dr. ClausGarbe - Oncology Management and Prevention - Lifetime achievement Award

University of Tuebingen - Germany

AUTHOR PROFILE

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Professor Claus Garbe embarked on his academic journey by obtaining his MD from the Free University of Berlin in 1983. Following this, he pursued board certification in Dermatology and Venereology in 1987. His early academic pursuits laid the foundation for his subsequent groundbreaking work in dermatology and oncology.

PROFESSIONAL ENDEAVORS:

In 1990, Professor Garbe achieved his habilitation, akin to a PhD equivalent, with a focus on the biology of melanoma cells. This marked a significant milestone in his academic career, demonstrating his commitment to advancing the understanding of melanoma, a deadly form of skin cancer. In 1995, he transitioned to Eberhard Karls University, Tuebingen, where he assumed the role of University Professor of Dermatology and Head of the Division of Dermatooncology. This move expanded his scope of influence and provided a platform for furthering his research and clinical endeavors.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY MANAGEMENT AND PREVENTION

Professor Garbe's contributions to the field of dermatology and oncology are extensive and profound. His principal research interests encompass the biology and genetics of melanoma and keratinocyte skin cancers, therapeutic trials in skin diseases, epidemiologic studies, and dermato-histopathology. Through his pioneering research, he has elucidated crucial mechanisms underlying skin cancer development and progression, paving the way for innovative therapeutic approaches and preventive strategies.

IMPACT AND INFLUENCE:

Professor Garbe's impact on the field of dermatologic oncology is unparalleled. His leadership roles in numerous multicenter clinical trials since 1989 have facilitated the translation of research findings into clinical practice, ultimately improving patient outcomes. Moreover, his presidency of the European Association of Dermatologic Oncology (EADO) underscores his influence on a global scale, driving collaboration and innovation in the fight against skin cancer.

ACADEMIC CITATIONS:

With over 800 articles and 17 textbooks to his name, Professor Garbe's scholarly output is prolific. His impressive H-index of 116 points reflects the significant impact of his work within the scientific community. His research findings have been cited extensively, highlighting their relevance and contribution to advancing knowledge in dermatology and oncology.

LEGACY AND FUTURE CONTRIBUTIONS:

Professor Garbe's legacy is characterized by his unwavering dedication to advancing the field of dermatologic oncology. His contributions have not only expanded our understanding of skin cancer but have also shaped clinical practice and guidelines. As he continues to spearhead research efforts and mentor the next generation of scientists and clinicians, his legacy is poised to endure, leaving an indelible mark on the field for years to come.

NOTABLE PUBLICATIONS

Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients. 2024 (2)

Sentinel lymph node biopsy for lentigo maligna melanoma under local anaesthesia. 2024 (3)

Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma. 2024 (1)

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. 2023 (6)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. 2023 (2)

Prof. Paolo De Simone – Oncology Therapy – Most Liked Article Award

Posted on by Pencis

Prof. Paolo De Simone - Oncology Therapy - Most Liked Article Award

UNIVERSITY OF PISA - Italy

Author Profile

Google Scholar
Scopus
Orcid

EARLY ACADEMIC PURSUITS

Paolo De Simone graduated summa cum laude in Medicine and Surgery from the University of Rome La Sapienza. His thesis was titled "Laparoscopic cholecystectomy in the treatment of gallstone lithiasis: prospective analysis of the results of our experience" under the supervision of Prof. Raffaello Cortesini.He earned his Specialist Diploma in General Surgery summa cum laude from the University of Rome “La Sapienza”. His thesis focused on "The role of laparoscopic surgery in the treatment of benign and malignant gastric pathologies" under the guidance of Prof. Raffaello Cortesini.Paolo De Simone achieved his PhD summa cum laude in Surgical Pathophysiology.

PROFESSIONAL ENDEAVORS

Registered in the Order of Doctors-Surgeons and Dentists of the Province of Rome with registration number 46702. He also qualified to practice the medical-surgical profession at the University of Rome “La Sapienza”. He served as a Foreign Resident-Assistant at the General Surgery Service of CHU André Vésale, Université Libre de Bruxelles, Montigny-Le-Tilleul, Belgium, and at the Thoracic and Vascular Surgery Service of the Hospital Avicenne, Bobigny, France. Paolo De Simone held several medical director positions:General Surgery Unit, Civil Hospital of Vittorio Veneto (TV),Organ Transplant Unit, San Salvatore Civil Hospital, L'Aquila,Service de Chirurgie Digestive, Hopital Erasme, Université Libre de Bruxelles, Brussels,University Liver Transplantology Unit, Pisa University Hospital.Currently, he is an Associate Professor of Surgery at the University of Pisa. He was elected Director of the School of Specialization in Surgery of the Digestive System and serves as Director of the Liver Surgery and Liver Transplant Unit, AOUP.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY THERAPY

Appointed as the Coordinator of the regional liver transplant program by DGRT of 17 December 2018, n. 1450. He also managed clinical, scientific, and educational coordination of terminal liver failure and liver transplantation (DG AOUP Resolution 852 of 09/20/2023).His research has covered areas like laparoscopic cholecystectomy, treatment of benign and malignant gastric pathologies, and liver transplantology.

IMPACT AND INFLUENCE

As Coordinator of the Liver Transplant Program of the Tuscany Region, he has significantly contributed to the advancement of liver transplantation in the region.

LEGACY AND FUTURE CONTRIBUTIONS

Paolo De Simone's legacy lies in his extensive contributions to the fields of general surgery, liver surgery, and liver transplantology. His future contributions are anticipated in enhancing liver transplant programs, furthering research in surgical pathophysiology, and mentoring the next generation of surgeons through his academic roles.

NOTABLE PUBLICATIONS

Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation.

First-in-human liver transplantation from a centenarian deceased donor after brain death.

Aging with a Liver Graft: Analysis of Very Long-Term Survivors after Liver Transplantation.

An Unexpected Case of Opisthorchis felineus Infection Revealed during Liver Transplantation.

An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients.

 

Dr. Francesco Raspagliesi – Gynecologic Oncology – Best Researcher Award

Posted on by Pencis

Dr. Francesco Raspagliesi - Gynecologic Oncology - Best Researcher Award

Fondazione IRCCS Istituto nazionale Tumori di Milano - Italy  

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Francesco Raspagliesi began his academic journey with a Degree in Medicine and Surgery from the University of Catania, Italy, which he completed on March 7, 1981. Following this foundational education, he obtained qualifications to practice medicine in 1981 and specialized in Obstetrics and Gynecology from the University of Catania in 1985 and 1988. These early academic pursuits laid the groundwork for his future professional endeavors in the field of gynecologic oncology.

PROFESSIONAL ENDEAVORS

From 1985 to 1992, Raspagliesi served as a Research Fellow at the Fondazione IRCCS Istituto Nazionale Tumori di Milano. He continued his professional growth at the same institution, becoming a Dirigente Medico di 1° Livello from 1992 to 1999 and advancing to Dirigente Medico di 2° Livello Gynecologic Oncology Unit Director from 1999 to 2019. His long-standing association with the Fondazione IRCCS Istituto Nazionale Tumori di Milano demonstrates his commitment and dedication to the field of gynecologic oncology and patient care.

CONTRIBUTIONS AND RESEARCH FOCUS ON GYNECOLOGIC ONCOLOGY

Throughout his career, Raspagliesi has made significant contributions to the field of Obstetrics and Gynecology. His research and clinical work have focused on gynecologic oncology, particularly in the treatment and management of gynecologic cancers. His expertise and leadership as the Gynecologic Oncology Unit Director have contributed to advancements in the diagnosis, treatment, and care of patients with gynecologic cancers.

IMPACT AND INFLUENCE

As a respected figure in the field of gynecologic oncology, Raspagliesi's work has had a profound impact on patient care, research, and education. His leadership roles and contributions to research have helped shape the way gynecologic cancers are treated and managed, influencing clinical practice and improving patient outcomes.

LEGACY AND FUTURE CONTRIBUTIONS

Francesco Raspagliesi's legacy in the field of Obstetrics and Gynecology is characterized by his dedication to patient care, leadership in gynecologic oncology, and contributions to research and education. His continued commitment to advancing the field through research, mentorship, and clinical practice ensures that his influence will be felt by future generations of gynecologic oncologists.

NOTABLE PUBLICATIONS

Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.  2024

Sentinel node mapping in high-intermediate and high-risk endometrial cancer: Analysis of 5-year oncologic outcomes. 2024

Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.  2024

Impact of Cold Ischemia on the Stability of 1H-MRS-Detected Metabolic Profiles of Ovarian Cancer Specimens. 2024

Concurrent Endometrial Cancer in Women with Atypical Endometrial Hyperplasia: What Is the Predictive Value of Patient Characteristics? (2) 2024